Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00609895 |
To compare the percentage of subjects with a glucose measurement < than or = to 56 mg/dL at any point of the 8-point glucose profiles during 3 consecutive days before vs. 3 consecutive days after switching insulin glargine dosing time from bedtime to morning and vs. 3 consecutive days after switching back to bedtime dosing of insulin glargine.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus |
Drug: INSULIN GLARGINE Drug: Insulin Glargine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment |
Official Title: | The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing |
Enrollment: | 22 |
Study Start Date: | January 2004 |
Study Completion Date: | August 2004 |
Ages Eligible for Study: | 6 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | sanofi-aventis ( Study Director ) |
Study ID Numbers: | HOE901_4038 |
Study First Received: | January 24, 2008 |
Last Updated: | March 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00609895 |
Health Authority: | Mexico: Ministry of Health |
Metabolic Diseases Glargine Diabetes Mellitus Endocrine System Diseases Endocrinopathy |
Metabolic disorder Glucose Metabolism Disorders Hypoglycemia Insulin |
Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |